Advances in pancreatic cancer biomarkers
- PMID: 31044028
- PMCID: PMC6478006
- DOI: 10.4081/oncol.2019.410
Advances in pancreatic cancer biomarkers
Abstract
Biomarkers play an essential role in the management of patients with invasive cancers. Pancreatic ductal adenocarcinoma (PDC) associated with poor prognosis due to advanced presentation and limited therapeutic options. This is further complicated by absence of validated screening and predictive biomarkers for early diagnosis and precision treatments respectively. There is emerging data on biomarkers in pancreatic cancer in past two decades. So far, the CA 19-9 remains the only approved biomarker for diagnosis and response assessment but limited by low sensitivity and specificity. In this article, we aim to review current and future biomarkers that has potential serve as critical tools for early diagnostic, predictive and prognostic indications in pancreatic cancer.
Keywords: Pancreatic cancer; biomarkers.
References
-
- Ryan DP, Hong TS, Bardeesy N. Pancreatic Adenocarcinoma. N Engl J Med 2014;371:1039-49. - PubMed
-
- Simoes PK, Olson SH, Saldia A, Kurtz RC. Epidemiology of pancreatic adenocarcinoma. Chin Clin Oncol 2017;6:24. - PubMed
-
- Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. Cancer J Clin 2009;59:225-49. - PubMed
-
- American Cancer Society. What is pancreatic cancer? Available from: https://www.cancer.org/cancer/pancreaticcancer/about/what-is-pancreatic-...
-
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2014;136:E359-86. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
